Black Americans are twice as likely to develop Alzheimer’s disease compared to their non-Hispanic white counterparts, yet they remain significantly underrepresented in clinical trials for new treatments, diagnostics, and preventions. Despite projections indicating that nearly 40% of the over eight million Americans living with Alzheimer’s and related dementias will be Latino or Black by 2023, a stark contrast is seen in the racial composition of clinical study participants. Data from the Food & Drug Administration as of 2020 reveals that 75% of trial participants were white, with only 11% Hispanic, 8% Black, and 6% Asian.
This discrepancy raises concerns about the inclusivity and effectiveness of Alzheimer’s research, given the higher risk profiles of these underrepresented groups. The issue is compounded by limited access to trial centers for Black and Latino communities, often located in institutions serving predominantly white, higher-resourced populations. Efforts to bridge this gap are underway, with organizations like Latinos Against Alzheimer’s and African Americans Against Alzheimer’s working to increase awareness and participation in clinical trials among minority communities.
Indira Turney, a Caribbean neuroscientist and advocate, emphasizes the importance of having healthcare professionals of color to effectively reach and engage African American and Latino communities in Alzheimer’s research. The call for greater accountability and inclusivity in clinical trials is echoed by many in the field, aiming to ensure that advancements in Alzheimer’s treatment can benefit all segments of the population equitably.
See “Black Americans Have 2x the Alzheimer’s Risk—But They’re Underrepresented in Drug Trials” by Lauren Fetten on the Being Patient website (February 6th, 2024)
